Development and Validation of an HPTLC Method for Determination of Olanzapine in Formulations : New Planar Chromatography-Densitometry Methods for Determination of Drug Substances and FormulationsPATEL, Rashmin B; PATEL, Mrunali R; BHATT, Kashyap K et al.Journal of AOAC International. 2010, Vol 93, Num 3, pp 811-819, issn 1060-3271, 9 p.Article

Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute Agitation in schizophreniaKINON, Bruce J; AHL, Jonna; ROTELLI, Matthew D et al.The American journal of emergency medicine. 2004, Vol 22, Num 3, pp 181-186, issn 0735-6757, 6 p.Article

Hypersensitivity syndrome with olanzapine confirmed by patch testsPREVOST, Philippe; BEDRY, Regis; LACOSTE, Denis et al.EJD. European journal of dermatology. 2012, Vol 22, Num 1, pp 126-127, issn 1167-1122, 2 p.Article

Simultaneous Assay of Olanzapine and Fluoxetine in Tablets by Column High-Performance Liquid Chromatography and High-Performance Thin-Layer ChromatographySHAH, Charmy R; SHAH, Nehal J; SUHAGIA, Bhanubhai N et al.Journal of AOAC International. 2007, Vol 90, Num 6, pp 1573-1578, issn 1060-3271, 6 p.Article

Closed Symposium Practical Issues in Using OlanzapineThe Journal of clinical psychiatry. 1997, Vol 58, issn 0160-6689, 73 p., SUP10Conference Proceedings

Reversible leucopenia related to olanzapineMEISSNER, W; SCHMIDT, T; KUPSCH, A et al.Movement disorders. 1999, Vol 14, Num 5, pp 872-873, issn 0885-3185Article

Treatment-resistant schizophrenic Patients respond to clozapine after olanzapine non-responseCONLEY, R. R; TAMMINGA, C. A; KELLY, D. L et al.Biological psychiatry (1969). 1999, Vol 46, Num 1, pp 73-77, issn 0006-3223Conference Paper

Early relapse of psychotic symptoms after an initial response to olanzapine. CommentaryKOSTAKOGLU, A. E; REZAKI, M; GÖGÜS, A et al.Acta psychiatrica Scandinavica. 1999, Vol 100, Num 4, pp 312-315, issn 0001-690XArticle

Olanzapine-induced psychotic mania in bipolar schizo-affective disorderBENAZZI, F.European psychiatry. 1999, Vol 14, Num 7, pp 410-411, issn 0924-9338Article

Neuroleptic malignant syndrome associated with olanzapineJOHNSON, V; BRUXNER, G.Australian and New Zealand journal of psychiatry. 1998, Vol 32, Num 6, pp 884-886, issn 0004-8674Article

Effects of olanzapine and clozapine on memory acquisition, consolidation and retrieval in mice using the elevated plus maze testMUTLU, Oguz; ULAK, Güner; CELIKYURT, Ipek Komsuoglu et al.Neuroscience letters. 2011, Vol 501, Num 3, pp 143-147, issn 0304-3940, 5 p.Article

Olanzapine-induced glucose dysregulationBETTINGER, T. L; MENDELSON, S. C; DORSON, P. G et al.The Annals of pharmacotherapy. 2000, Vol 34, Num 7-8, pp 865-867, issn 1060-0280Article

Focus on schizophreniaTOLLEFSON, Gary D.British journal of psychiatry. Supplement. 1999, Vol 174, Num 37, issn 0960-5371, 46 p.Conference Proceedings

Olanzapine-induced weight gainGUPTA, S; DRONEY, T; AL-SAMARRAI, S et al.Annals of clinical psychiatry. 1998, Vol 10, Num 1, issn 1040-1237, p. 39Article

Olanzapine in treatment-resistant bipolar disorderMCELROY, S. L; FRYE, M; POST, R. M et al.Journal of affective disorders. 1998, Vol 49, Num 2, pp 119-122, issn 0165-0327Article

New antipsychotic medications : strategies for evaluation and selected findingsSCHOOLER, N. R.Schizophrenia research. 1997, Vol 27, Num 2-3, pp 249-259, issn 0920-9964Article

Disposition and biotransformation of the antipsychotic agent olanzapine in humansKASSAHUN, K; MATTIUZ, E; NYHART, E. JR et al.Drug metabolism and disposition. 1997, Vol 25, Num 1, pp 81-93, issn 0090-9556Article

Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patientsPERRY, P. J; SANGER, T; BEASLEY, C et al.Journal of clinical psychopharmacology. 1997, Vol 17, Num 6, pp 472-477, issn 0271-0749Article

Efficacy of atypical antipsychotics in mood disordersYATHAM, Lakshmi N.Journal of clinical psychopharmacology. 2003, Vol 23, Num 3, pp S9-S14, issn 0271-0749, SUP1Conference Paper

Diabète sous neuroleptiques = Diabetes under neuroleptic agentsLa Revue Prescrire. 2001, Vol 21, Num 223, issn 0247-7750, p. 834Article

Six-month outcomes for patients who switched to Olanzapine treatmentNOORDSY, Douglas L; O'KEEFE, Christopher; MUESER, Kim T et al.Psychiatric services (Washington, D.C.). 2001, Vol 52, Num 4, pp 501-507, issn 1075-2730Article

Impact clinique des neuroleptiques atypiques : étude prospective sur 6 mois en milieu hospitalier de patients traités par rispéridone ou olanzapine = Clinical impact of atypical antipsychotics: prospective 6-month study of inpatients treated by risperidone or olanzapineHAMEL, B; COURTET, P; VERGNES, C et al.Thérapie (Paris). 2001, Vol 56, Num 6, pp 645-652, issn 0040-5957, 8 p.Article

Disposition of olanzapine in Chinese schizophrenic patientsLANE, H. Y; LIU, H. C; VANDENBERG, C. M et al.International journal of clinical pharmacology and therapeutics. 2000, Vol 38, Num 10, pp 482-485, issn 0946-1965Article

Olanzapine response in psychotic depressionROTHSCHILD, A. J; BATES, K. S; BOEHRINGER, K. L et al.The Journal of clinical psychiatry. 1999, Vol 60, Num 2, pp 116-118, issn 0160-6689Article

Olanzapine overdose mimicking opioid intoxicationO'MALLEY, G. F; SEIFERT, S; HEARD, K et al.Annals of emergency medicine. 1999, Vol 34, Num 2, pp 279-281, issn 0196-0644Article